Published in J Steroid Biochem Mol Biol on May 19, 2009
Estrogen Receptor-β Up-Regulates IGF1R Expression and Activity to Inhibit Apoptosis and Increase Growth of Medulloblastoma. Endocrinology (2015) 2.03
Combining the multitargeted tyrosine kinase inhibitor vandetanib with the antiestrogen fulvestrant enhances its antitumor effect in non-small cell lung cancer. J Thorac Oncol (2012) 1.60
Estrogen receptor signaling in lung cancer. Semin Oncol (2009) 1.36
Combined analysis of estrogen receptor beta-1 and progesterone receptor expression identifies lung cancer patients with poor outcome. Clin Cancer Res (2010) 1.17
Estrogen receptor agonists and estrogen attenuate TNF-α-induced apoptosis in VSC4.1 motoneurons. J Endocrinol (2010) 1.07
Estrogen receptors alpha (ERα) and beta (ERβ): subtype-selective ligands and clinical potential. Steroids (2014) 1.07
Raloxifene inhibits growth of RT4 urothelial carcinoma cells via estrogen receptor-dependent induction of apoptosis and inhibition of proliferation. Horm Cancer (2012) 1.00
Progesterone and estrogen receptor expression and activity in human non-small cell lung cancer. Steroids (2011) 0.98
Expression levels of estrogen receptor beta in conjunction with aromatase predict survival in non-small cell lung cancer. Lung Cancer (2011) 0.94
Co-expression of GPR30 and ERbeta and their association with disease progression in uterine carcinosarcoma. Am J Obstet Gynecol (2010) 0.93
Antiestrogen fulvestrant enhances the antiproliferative effects of epidermal growth factor receptor inhibitors in human non-small-cell lung cancer. J Thorac Oncol (2013) 0.91
Interactions between IGF-I, estrogen receptor-α (ERα), and ERβ in regulating growth/apoptosis of MCF-7 human breast cancer cells. J Endocrinol (2010) 0.90
Estrongenic steroid hormones in lung cancer. Semin Oncol (2013) 0.89
Overexpression and gender-specific differences of SRC-3 (SRC-3/AIB1) immunoreactivity in human non-small cell lung cancer: an in vivo study. J Histochem Cytochem (2010) 0.86
Prevention of tobacco carcinogen-induced lung cancer in female mice using antiestrogens. Carcinogenesis (2012) 0.86
The role of estrogen, progesterone and aromatase in human non-small-cell lung cancer. Lung Cancer Manag (2012) 0.85
Smoking out reproductive hormone actions in lung cancer. Mol Cancer Res (2014) 0.83
Intratumoral localization and activity of 17β-hydroxysteroid dehydrogenase type 1 in non-small cell lung cancer: a potent prognostic factor. J Transl Med (2013) 0.82
Correlation between epidermal growth factor receptor mutations and nuclear expression of female hormone receptors in non-small cell lung cancer: a meta-analysis. J Thorac Dis (2015) 0.78
Potential therapeutic benefit of combining gefitinib and tamoxifen for treating advanced lung adenocarcinoma. Biomed Res Int (2015) 0.78
Exploring estrogenic activity in lung cancer. Mol Biol Rep (2016) 0.77
Estrogen upregulates MICA/B expression in human non-small cell lung cancer through the regulation of ADAM17. Cell Mol Immunol (2014) 0.77
Overexpression of estrogen receptor beta is a prognostic marker in non-small cell lung cancer: a meta-analysis. Int J Clin Exp Med (2015) 0.77
Targeting the estrogen pathway for the treatment and prevention of lung cancer. Lung Cancer Manag (2014) 0.77
Expression of PAM50 Genes in Lung Cancer: Evidence that Interactions between Hormone Receptors and HER2/HER3 Contribute to Poor Outcome. Neoplasia (2015) 0.75
Differential Effects of E2 on MAPK Activity in the Brain and Heart of Aged Female Rats. PLoS One (2016) 0.75
Biologic roles of estrogen receptor-β and insulin-like growth factor-2 in triple-negative breast cancer. Biomed Res Int (2015) 0.75
Correlation between epidermal growth factor receptor mutations and the expression of estrogen receptor-β in advanced non-small cell lung cancer. Oncol Lett (2017) 0.75
Global cancer statistics, 2002. CA Cancer J Clin (2005) 119.22
Cancer statistics, 2007. CA Cancer J Clin (2007) 53.49
Pyrazole ligands: structure-affinity/activity relationships and estrogen receptor-alpha-selective agonists. J Med Chem (2000) 3.34
Estrogen receptor-beta potency-selective ligands: structure-activity relationship studies of diarylpropionitriles and their acetylene and polar analogues. J Med Chem (2001) 3.24
Estrogen signaling: a subtle balance between ER alpha and ER beta. Mol Interv (2003) 2.88
Extranuclear steroid receptors: nature and actions. Endocr Rev (2007) 2.72
Human non-small cell lung tumors and cells derived from normal lung express both estrogen receptor alpha and beta and show biological responses to estrogen. Cancer Res (2002) 2.52
Combined targeting of the estrogen receptor and the epidermal growth factor receptor in non-small cell lung cancer shows enhanced antiproliferative effects. Cancer Res (2005) 2.28
Estrogen receptor signaling pathways in human non-small cell lung cancer. Steroids (2007) 1.80
Estrogen receptor alpha and beta are prognostic factors in non-small cell lung cancer. Clin Cancer Res (2005) 1.73
Fulvestrant: an oestrogen receptor antagonist with a novel mechanism of action. Br J Cancer (2004) 1.72
Expression, function, and clinical implications of the estrogen receptor beta in human lung cancers. Biochem Biophys Res Commun (2001) 1.67
Response-specific and ligand dose-dependent modulation of estrogen receptor (ER) alpha activity by ERbeta in the uterus. Endocrinology (2003) 1.66
Nuclear estrogen receptor beta in lung cancer: expression and survival differences by sex. Clin Cancer Res (2005) 1.59
Estrogen and growth factor receptor interactions in human breast and non-small cell lung cancer cells. Steroids (2005) 1.57
Aromatase inhibitors in human lung cancer therapy. Cancer Res (2005) 1.55
The significance of estrogen receptor beta in 301 surgically treated non-small cell lung cancers. J Thorac Cardiovasc Surg (2005) 1.55
Conformational changes and coactivator recruitment by novel ligands for estrogen receptor-alpha and estrogen receptor-beta: correlations with biological character and distinct differences among SRC coactivator family members. Endocrinology (2000) 1.50
Regulation of postnatal lung development and homeostasis by estrogen receptor beta. Mol Cell Biol (2003) 1.44
Regulation of endogenous gene expression in human non-small cell lung cancer cells by estrogen receptor ligands. Cancer Res (2005) 1.40
Lung dysfunction causes systemic hypoxia in estrogen receptor beta knockout (ERbeta-/-) mice. Proc Natl Acad Sci U S A (2006) 1.37
Evidence for autocrine actions of neuromedin B and gastrin-releasing peptide in non-small cell lung cancer. Pulm Pharmacol Ther (1999) 1.37
Estrogen promotes tumor progression in a genetically defined mouse model of lung adenocarcinoma. Endocr Relat Cancer (2008) 1.34
Evaluation of ligand selectivity using reporter cell lines stably expressing estrogen receptor alpha or beta. Biochem Pharmacol (2006) 1.33
Oestrogen receptor beta over expression in males with non-small cell lung cancer is associated with better survival. Lung Cancer (2007) 1.32
Nongenomic beta estrogen receptors enhance beta1 adrenergic signaling induced by the nicotine-derived carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone in human small airway epithelial cells. Cancer Res (2007) 1.18
Estrogen receptor beta functions through nongenomic mechanisms in lung cancer cells. Mol Endocrinol (2008) 1.14
CYP24, the enzyme that catabolizes the antiproliferative agent vitamin D, is increased in lung cancer. Int J Cancer (2006) 1.12
Estradiol and nicotine exposure enhances A549 bronchioloalveolar carcinoma xenograft growth in mice through the stimulation of angiogenesis. Int J Oncol (2006) 1.05
Hormone replacement therapy in menopause and lung cancer: an update. Eur J Cancer Prev (2006) 0.79
High false-negative rate of HER2 quantitative reverse transcription polymerase chain reaction of the Oncotype DX test: an independent quality assurance study. J Clin Oncol (2011) 4.70
The Pittsburgh Lung Screening Study (PLuSS): outcomes within 3 years of a first computed tomography scan. Am J Respir Crit Care Med (2008) 4.22
Association of radiographic emphysema and airflow obstruction with lung cancer. Am J Respir Crit Care Med (2008) 3.94
Human non-small cell lung tumors and cells derived from normal lung express both estrogen receptor alpha and beta and show biological responses to estrogen. Cancer Res (2002) 2.52
Combined targeting of the estrogen receptor and the epidermal growth factor receptor in non-small cell lung cancer shows enhanced antiproliferative effects. Cancer Res (2005) 2.28
MicroRNA signature distinguishes the degree of aggressiveness of papillary thyroid carcinoma. Ann Surg Oncol (2011) 2.25
Progress in chemoprevention drug development: the promise of molecular biomarkers for prevention of intraepithelial neoplasia and cancer--a plan to move forward. Clin Cancer Res (2006) 2.24
Anatomic segmentectomy for the solitary pulmonary nodule and early-stage lung cancer. Ann Thorac Surg (2012) 2.14
Doubling times and CT screen–detected lung cancers in the Pittsburgh Lung Screening Study. Am J Respir Crit Care Med (2012) 1.90
SRC family kinases mediate epidermal growth factor receptor ligand cleavage, proliferation, and invasion of head and neck cancer cells. Cancer Res (2004) 1.88
A sensitive non-radioactive northern blot method to detect small RNAs. Nucleic Acids Res (2010) 1.81
Phosphorylation of TNF-alpha converting enzyme by gastrin-releasing peptide induces amphiregulin release and EGF receptor activation. Proc Natl Acad Sci U S A (2006) 1.68
Unlocking biomarker discovery: large scale application of aptamer proteomic technology for early detection of lung cancer. PLoS One (2010) 1.66
A multiplexed serum biomarker immunoassay panel discriminates clinical lung cancer patients from high-risk individuals found to be cancer-free by CT screening. J Thorac Oncol (2012) 1.63
Combined inhibition of c-Src and epidermal growth factor receptor abrogates growth and invasion of head and neck squamous cell carcinoma. Clin Cancer Res (2008) 1.63
Combining the multitargeted tyrosine kinase inhibitor vandetanib with the antiestrogen fulvestrant enhances its antitumor effect in non-small cell lung cancer. J Thorac Oncol (2012) 1.60
HGF and c-Met participate in paracrine tumorigenic pathways in head and neck squamous cell cancer. Clin Cancer Res (2009) 1.57
Phase II study of induction fixed-dose rate gemcitabine and bevacizumab followed by 30 Gy radiotherapy as preoperative treatment for potentially resectable pancreatic adenocarcinoma. Ann Surg Oncol (2013) 1.46
Downregulation of Dkk3 activates beta-catenin/TCF-4 signaling in lung cancer. Carcinogenesis (2007) 1.46
miRNA expression profiling of lung adenocarcinomas: correlation with mutational status. Mod Pathol (2010) 1.46
(-)-Gossypol acts directly on the mitochondria to overcome Bcl-2- and Bcl-X(L)-mediated apoptosis resistance. Mol Cancer Ther (2005) 1.45
Regulation of endogenous gene expression in human non-small cell lung cancer cells by estrogen receptor ligands. Cancer Res (2005) 1.40
Diagnostic accuracy of MALDI mass spectrometric analysis of unfractionated serum in lung cancer. J Thorac Oncol (2007) 1.40
Estrogen receptor signaling in lung cancer. Semin Oncol (2009) 1.36
Cross-talk between G protein-coupled receptor and epidermal growth factor receptor signaling pathways contributes to growth and invasion of head and neck squamous cell carcinoma. Cancer Res (2006) 1.35
Clinicopathological predictors of EGFR/KRAS mutational status in primary lung adenocarcinomas. Mod Pathol (2009) 1.32
Antitumor mechanisms of combined gastrin-releasing peptide receptor and epidermal growth factor receptor targeting in head and neck cancer. Mol Cancer Ther (2007) 1.29
Cross-talk between estrogen receptor and epidermal growth factor receptor in head and neck squamous cell carcinoma. Clin Cancer Res (2009) 1.26
Fibulin-5 suppresses lung cancer invasion by inhibiting matrix metalloproteinase-7 expression. Cancer Res (2009) 1.25
Safety and efficacy of combination immunotherapy with interferon alfa-2b and tremelimumab in patients with stage IV melanoma. J Clin Oncol (2011) 1.24
Prediction of the Oncotype DX recurrence score: use of pathology-generated equations derived by linear regression analysis. Mod Pathol (2013) 1.23
Aberrant promoter methylation of p16 and MGMT genes in lung tumors from smoking and never-smoking lung cancer patients. Neoplasia (2006) 1.22
Phase II study of everolimus (RAD001) in previously treated small cell lung cancer. Clin Cancer Res (2010) 1.20
Increased levels of tumor-infiltrating lymphocytes are associated with improved recurrence-free survival in stage 1A non-small-cell lung cancer. J Surg Res (2011) 1.20
Frequent inactivation of RAMP2, EFEMP1 and Dutt1 in lung cancer by promoter hypermethylation. Clin Cancer Res (2007) 1.19
Molecular analysis of plasma DNA for the early detection of lung cancer by quantitative methylation-specific PCR. Clin Cancer Res (2010) 1.18
Nicotine activates cell-signaling pathways through muscle-type and neuronal nicotinic acetylcholine receptors in non-small cell lung cancer cells. Pulm Pharmacol Ther (2006) 1.17
Combined analysis of estrogen receptor beta-1 and progesterone receptor expression identifies lung cancer patients with poor outcome. Clin Cancer Res (2010) 1.17
Dual blockade of EGFR and c-Met abrogates redundant signaling and proliferation in head and neck carcinoma cells. Clin Cancer Res (2011) 1.15
Estrogen receptor pathways in lung cancer. Curr Oncol Rep (2004) 1.15
Impact of tumor size on outcomes after anatomic lung resection for stage 1A non-small cell lung cancer based on the current staging system. J Thorac Cardiovasc Surg (2011) 1.15
c-Src activation mediates erlotinib resistance in head and neck cancer by stimulating c-Met. Clin Cancer Res (2012) 1.15
Management of patients treated with chemoradiotherapy for head and neck cancer without prophylactic feeding tubes: the University of Pittsburgh experience. Laryngoscope (2010) 1.14
Nicotine signals through muscle-type and neuronal nicotinic acetylcholine receptors in both human bronchial epithelial cells and airway fibroblasts. Respir Res (2004) 1.14
The incidence of arm edema in women with breast cancer randomized on the National Surgical Adjuvant Breast and Bowel Project study B-04 to radical mastectomy versus total mastectomy and radiotherapy versus total mastectomy alone. Int J Radiat Oncol Biol Phys (2007) 1.13
NY-ESO-1 119-143 is a promiscuous major histocompatibility complex class II T-helper epitope recognized by Th1- and Th2-type tumor-reactive CD4+ T cells. Cancer Res (2002) 1.13
Differing patterns of circulating regulatory T cells and myeloid-derived suppressor cells in metastatic melanoma patients receiving anti-CTLA4 antibody and interferon-α or TLR-9 agonist and GM-CSF with peptide vaccination. J Immunother (2012) 1.13
Vorinostat increases carboplatin and paclitaxel activity in non-small-cell lung cancer cells. Int J Cancer (2010) 1.13
CYP24, the enzyme that catabolizes the antiproliferative agent vitamin D, is increased in lung cancer. Int J Cancer (2006) 1.12
Tumor epidermal growth factor receptor and EGFR PY1068 are independent prognostic indicators for head and neck squamous cell carcinoma. Clin Cancer Res (2012) 1.12
Optimal threshold in CT quantification of emphysema. Eur Radiol (2012) 1.12
CT based computerized identification and analysis of human airways: a review. Med Phys (2012) 1.11
Gastrin-releasing peptide receptor-mediated autocrine growth in squamous cell carcinoma of the head and neck. J Natl Cancer Inst (2002) 1.11
Pilot study of gefitinib and fulvestrant in the treatment of post-menopausal women with advanced non-small cell lung cancer. Lung Cancer (2008) 1.11
Hormone replacement therapy and decreased lung cancer survival. J Clin Oncol (2005) 1.10
Lung cancer serum biomarker discovery using glycoprotein capture and liquid chromatography mass spectrometry. J Proteome Res (2010) 1.10
Gastrin-releasing peptide activates Akt through the epidermal growth factor receptor pathway and abrogates the effect of gefitinib. Exp Cell Res (2007) 1.09
The relationship between body mass index and unintended pregnancy: results from the 2002 National Survey of Family Growth. Contraception (2008) 1.08
Therapeutic targeting of human hepatocyte growth factor with a single neutralizing monoclonal antibody reduces lung tumorigenesis. Mol Cancer Ther (2008) 1.07
Gastrin-releasing peptide receptor mediates activation of the epidermal growth factor receptor in lung cancer cells. Neoplasia (2005) 1.06
Acceptability of contraceptive-induced amenorrhea in a racially diverse group of US women. Contraception (2007) 1.06
Multiplexed analysis of serum cytokines as biomarkers in squamous cell carcinoma of the head and neck patients. Laryngoscope (2005) 1.02
Hepatocyte growth factor and other fibroblast secretions modulate the phenotype of human bronchial epithelial cells. Am J Physiol Lung Cell Mol Physiol (2007) 1.02
Targeting of Both the c-Met and EGFR Pathways Results in Additive Inhibition of Lung Tumorigenesis in Transgenic Mice. Cancers (Basel) (2010) 1.02
Comparison of p53 mutations between adenocarcinoma and squamous cell carcinoma of the lung: unique spectra involving G to A transitions and G to T transversions in both histologic types. Lung Cancer (2003) 1.01
Immunohistochemical analysis of phosphotyrosine signal transducer and activator of transcription 3 and epidermal growth factor receptor autocrine signaling pathways in head and neck cancers and metastatic lymph nodes. Clin Cancer Res (2008) 1.00
Sex and gender differences in lung cancer. J Gend Specif Med (2003) 0.99
Signaling pathways involved in cyclooxygenase-2 induction by hepatocyte growth factor in non small-cell lung cancer. Mol Pharmacol (2007) 0.97
Genetic determinants for promoter hypermethylation in the lungs of smokers: a candidate gene-based study. Cancer Res (2011) 0.97
Transgenic mice overexpressing hepatocyte growth factor in the airways show increased susceptibility to lung cancer. Carcinogenesis (2006) 0.97
An economic comparison of female sterilization of hysteroscopic tubal occlusion with laparoscopic bilateral tubal ligation. Contraception (2009) 0.96
The diagnostic utility of p16 FISH and GLUT-1 immunohistochemical analysis in mesothelial proliferations. Am J Clin Pathol (2011) 0.95
EGFR fluorescence in situ hybridization-positive lung adenocarcinoma: incidence of coexisting KRAS and BRAF mutations. Hum Pathol (2010) 0.94
Non-small-cell lung cancer and breast carcinoma: chemotherapy and beyond. Lancet Oncol (2006) 0.93
Prognostic significance of p16/cdkn2a loss in pleural malignant mesotheliomas. Virchows Arch (2008) 0.93
Morphologic and clinicopathologic features of lung squamous cell carcinomas expressing Sox2. Am J Clin Pathol (2012) 0.92
Association of the DNA repair gene XPD Asp312Asn polymorphism with p53 gene mutations in tobacco-related non-small cell lung cancer. Carcinogenesis (2003) 0.91
CYP24 inhibition preserves 1α,25-dihydroxyvitamin D(3) anti-proliferative signaling in lung cancer cells. Mol Cell Endocrinol (2012) 0.91
Serum biomarker profiles as diagnostic tools in lung cancer. Cancer Biomark (2012) 0.91
Inhibition of the splicing of glucose-6-phosphate dehydrogenase precursor mRNA by polyunsaturated fatty acids. J Biol Chem (2002) 0.91
Nutritional regulation of mRNA processing. J Nutr (2004) 0.89
Genetic variability in DNA repair and cell cycle control pathway genes and risk of smoking-related lung cancer. Mol Carcinog (2011) 0.89
Mutation and polymorphism in the EGFR-TK domain associated with lung cancer. J Thorac Oncol (2006) 0.89